Insulin glargine + insulin lispro

Insulin glargine + insulin lispro is a combination regimen of two distinct insulins used in the management of diabetes mellitus. Insulin glargine is a long-acting, recombinant human insulin analog that provides basal glycemic control for up to 24 hours or longer, while insulin lispro is a rapid-acting analog designed to manage postprandial blood glucose spikes. This combination therapy mimics physiological insulin secretion by providing both steady background (basal) and mealtime (bolus) coverage. Both agents act by binding to the human insulin receptor and promoting cellular uptake of glucose, thereby lowering blood sugar levels in patients with type 1 or type 2 diabetes[1][2][8]. Insulin glargine was developed by Sanofi, while various companies manufacture both insulins under different brand names.

Brand names

LantusHumalog

Other names

glargine + Humalog